8-K: Xilio Therapeutics Moves to Nasdaq Capital Market

Xilio Therapeutics' common stock will transfer to The Nasdaq Capital Market on October 6, 2025, after failing to meet the $1.00 minimum bid price requirement, granting the company an additional 180 days to regain compliance.

Summary

• Xilio Therapeutics, Inc. received approval from Nasdaq to transfer its common stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market.
• The transfer is effective as of the opening of business on October 6, 2025, and the common stock will continue to trade under the symbol XLO.
• This transfer stems from the company's failure to maintain the $1.00 minimum bid price required for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), as previously disclosed on April 8, 2025.
• Nasdaq has granted an additional 180 calendar day period, until March 30, 2026, for the company to regain compliance with the Minimum Bid Price Requirement.
• To regain compliance, the common stock must close at $1.00 or more for at least 10 consecutive business days during this grace period.

Sentiment

Score: 4

Explanation: The transfer to a lower Nasdaq market tier due to non-compliance with the minimum bid price requirement is a significant negative indicator. However, the granting of an additional 180-day compliance period offers a window for the company to rectify the situation, preventing immediate delisting.

Positives

• Nasdaq granted an additional 180 calendar day period, until March 30, 2026, to regain compliance with the minimum bid price requirement, providing more time to address the issue.
• The common stock will continue to trade on a Nasdaq market (The Nasdaq Capital Market) under the same symbol (XLO), maintaining liquidity and visibility.

Negatives

• The company failed to maintain the $1.00 minimum bid price, leading to a transfer from the more prestigious Nasdaq Global Select Market to The Nasdaq Capital Market.
• The underlying issue of a low share price indicates potential investor concern or operational challenges.

Risks

• Failure to regain compliance with the $1.00 minimum bid price requirement by March 30, 2026, could lead to further delisting actions.
• The transfer to The Nasdaq Capital Market may impact investor perception and liquidity of the company's stock.
• The company's ability to implement effective strategies to increase its share price remains uncertain.

Future Outlook

The company is actively evaluating available options to regain compliance with the Nasdaq Minimum Bid Price Requirement by the extended deadline of March 30, 2026.

Management Comments

• "The Company is continuing to evaluate available options to regain compliance with the Minimum Bid Requirement."

Industry Context

Small-cap biotechnology companies often face challenges in maintaining stock exchange listing requirements, particularly the minimum bid price, due to volatile market conditions, clinical trial outcomes, and funding needs. Transfers to lower-tier markets like the Nasdaq Capital Market are not uncommon for companies seeking additional time to improve their financial standing or operational performance, though it can signal increased risk to investors.

Stakeholder Impact

• Shareholders: May experience increased uncertainty and potential volatility due to the listing transfer and the ongoing compliance challenge. The move to a lower-tier market could also affect liquidity and investor perception.
• Employees: No direct impact mentioned, but prolonged stock price issues could indirectly affect morale or stock-based compensation value.

Next Steps

• The company must ensure its common stock closes at $1.00 or more for at least 10 consecutive business days by March 30, 2026, to regain compliance with Nasdaq's Minimum Bid Price Requirement.
• Management will continue to evaluate and implement strategies to improve the company's share price.

Key Dates

Recommendation

While the transfer to the Nasdaq Capital Market due to minimum bid price non-compliance is a negative signal, the granted 180-day extension provides a critical window for Xilio Therapeutics to regain compliance. A 'hold' recommendation is appropriate for existing investors to monitor the company's efforts to address its share price and avoid immediate losses, but new investment should be approached with extreme caution given the inherent risks and the company's current precarious position. The situation warrants close observation of upcoming strategic announcements and financial performance.

Keywords

Xilio Therapeutics, Nasdaq, Delisting, Minimum Bid Price, Stock Listing, XLO, Compliance, Capital Market, Global Select Market